Abstract
On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years. The ACIP JE Vaccine Workgroup reviewed the epidemiology of JE in travelers and evaluated published and unpublished data on JE-VC immunogenicity and safety in adults and children. The evidence for benefits and risks associated with JE-VC vaccination of children was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and outlines the recommendations for use of JE-VC in children traveling to JE-endemic countries.
TY - JOUR
T1 - Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013.
A1 - ,,
PY - 2013/11/15/entrez
PY - 2013/11/15/pubmed
PY - 2014/1/7/medline
SP - 898
EP - 900
JF - MMWR. Morbidity and mortality weekly report
JO - MMWR Morb Mortal Wkly Rep
VL - 62
IS - 45
N2 - On June 19, 2013, the Advisory Committee on Immunization Practices (ACIP) voted to extend existing recommendations for use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) (Ixiaro, Intercell Biomedical) to include children aged 2 months through 16 years. The ACIP JE Vaccine Workgroup reviewed the epidemiology of JE in travelers and evaluated published and unpublished data on JE-VC immunogenicity and safety in adults and children. The evidence for benefits and risks associated with JE-VC vaccination of children was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. This report summarizes the evidence considered by ACIP and outlines the recommendations for use of JE-VC in children traveling to JE-endemic countries.
SN - 1545-861X
UR - https://www.unboundmedicine.com/medline/citation/24226626/full_citation
L2 - https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6245a3.htm
DB - PRIME
DP - Unbound Medicine
ER -